Friday, July 10, 2026

Drug profile · INN

thiethylperazine malate

thiethylperazine malate (TORECAN) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — thiethylperazine malate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

thiethylperazine malate (TORECAN) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN thiethylperazine malate
Brand TORECAN
Mechanism Dopamine D2 receptor antagonist
Target D(2) dopamine receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Dopamine D2 receptor antagonist

Primary target: D(2) dopamine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. cabergoline Dopamine D2 receptor agonist
  4. clozapine Serotonin 2a (5-HT2a) receptor antagonist
  5. fluphenazine decanoate Dopamine D2 receptor antagonist
  6. fluphenazine hydrochloride Dopamine D2 receptor antagonist

Frequently asked questions

What is thiethylperazine malate?

thiethylperazine malate (TORECAN) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for thiethylperazine malate?

TORECAN is a marketed brand name for thiethylperazine malate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of thiethylperazine malate?

thiethylperazine malate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.